697 related articles for article (PubMed ID: 18050251)
41. Elevated levels of leukotriene B4 and leukotriene E4 in bronchoalveolar lavage fluid from patients with scleroderma lung disease.
Kowal-Bielecka O; Distler O; Kowal K; Siergiejko Z; Chwiećko J; Sulik A; Gay RE; Łukaszyk AB; Gay S; Sierakowski S
Arthritis Rheum; 2003 Jun; 48(6):1639-46. PubMed ID: 12794832
[TBL] [Abstract][Full Text] [Related]
42. Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II.
Volkmann ER; Tashkin DP; Sim M; Li N; Khanna D; Roth MD; Clements PJ; Hoffmann-Vold AM; Furst DE; Kim G; Goldin J; Elashoff RM
J Rheumatol; 2019 Oct; 46(10):1316-1325. PubMed ID: 30770517
[TBL] [Abstract][Full Text] [Related]
43. Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study.
Theodore AC; Tseng CH; Li N; Elashoff RM; Tashkin DP
Chest; 2012 Sep; 142(3):614-621. PubMed ID: 22156609
[TBL] [Abstract][Full Text] [Related]
44. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma.
Garin MC; Highland KB; Silver RM; Strange C
J Rheumatol; 2009 Feb; 36(2):330-6. PubMed ID: 19208563
[TBL] [Abstract][Full Text] [Related]
45. Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis.
De Santis M; Bosello S; La Torre G; Capuano A; Tolusso B; Pagliari G; Pistelli R; Danza FM; Zoli A; Ferraccioli G
Respir Res; 2005 Aug; 6(1):96. PubMed ID: 16107215
[TBL] [Abstract][Full Text] [Related]
46. Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders.
Iudici M; Cuomo G; Vettori S; Bocchino M; Sanduzzi Zamparelli A; Cappabianca S; Valentini G
Semin Arthritis Rheum; 2015 Feb; 44(4):437-44. PubMed ID: 25282395
[TBL] [Abstract][Full Text] [Related]
47. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease.
Trad S; Amoura Z; Beigelman C; Haroche J; Costedoat N; Boutin le TH; Cacoub P; Frances C; Wechsler B; Grenier P; Piette JC
Arthritis Rheum; 2006 Jan; 54(1):184-91. PubMed ID: 16385514
[TBL] [Abstract][Full Text] [Related]
48. Comparison of induced sputum and bronchoalveolar lavage in lung transplant recipients.
Mamessier E; Milhe F; Badier M; Thomas P; Magnan A; Reynaud-Gaubert M
J Heart Lung Transplant; 2006 May; 25(5):523-32. PubMed ID: 16678030
[TBL] [Abstract][Full Text] [Related]
49. [Bronchoalveolar lavage findings in the pulmonary impairment related to systemic sclerosis].
Ioanăş M; Ioniţă D; Cerviş L; Bîscă N; Serbănescu A; Nicolau A
Pneumologia; 2002; 51(3):203-5. PubMed ID: 12602092
[TBL] [Abstract][Full Text] [Related]
50. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease.
Roth MD; Tseng CH; Clements PJ; Furst DE; Tashkin DP; Goldin JG; Khanna D; Kleerup EC; Li N; Elashoff D; Elashoff RM;
Arthritis Rheum; 2011 Sep; 63(9):2797-808. PubMed ID: 21547897
[TBL] [Abstract][Full Text] [Related]
51. Bronchoalveolar matrix metalloproteinase 9 relates to restrictive lung function impairment in systemic sclerosis.
Andersen GN; Nilsson K; Pourazar J; Hackett TL; Kazzam E; Blomberg A; Waldenström A; Warner J; Rantapää-Dahlqvist S; Mincheva-Nilsson L; Sandström T
Respir Med; 2007 Oct; 101(10):2199-206. PubMed ID: 17643278
[TBL] [Abstract][Full Text] [Related]
52. Bronchoalveolar lavage in other interstitial lung diseases.
Costabel U; Guzman J; Bonella F; Oshimo S
Semin Respir Crit Care Med; 2007 Oct; 28(5):514-24. PubMed ID: 17975779
[TBL] [Abstract][Full Text] [Related]
53. The efficacy of treatment for systemic sclerosis interstitial lung disease: results from a meta-analysis.
Broad K; Pope JE
Med Sci Monit; 2010 Sep; 16(9):RA187-90. PubMed ID: 20802426
[TBL] [Abstract][Full Text] [Related]
54. Pulmonary injury in patients undergoing complex spine surgery.
Urban MK; Jules-Elysee KM; Beckman JB; Sivjee K; King T; Kelsey W; Boachie-Adjei O
Spine J; 2005; 5(3):269-76. PubMed ID: 15863083
[TBL] [Abstract][Full Text] [Related]
55. A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma.
Domiciano DS; Bonfá E; Borges CT; Kairalla RA; Capelozzi VL; Parra E; Christmann RB
Clin Rheumatol; 2011 Feb; 30(2):223-9. PubMed ID: 20544245
[TBL] [Abstract][Full Text] [Related]
56. [Pulmonary manifestations of systemic scleroderma: pathophysiologic and clinical significance of the activation of lung fibroblasts].
Behr J; Adelmann-Grill BC; Hein R; Schwaiblmair M; Degenkolb B; Krombach F; Fruhmann G
Pneumologie; 1995 Apr; 49(4):266-72. PubMed ID: 7792285
[TBL] [Abstract][Full Text] [Related]
57. Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease.
Valentini G; Paone C; La Montagna G; Chiarolanza I; Menegozzo M; Colutta E; Ruocco L
Scand J Rheumatol; 2006; 35(1):35-8. PubMed ID: 16467039
[TBL] [Abstract][Full Text] [Related]
58. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement.
Steen V; Medsger TA
Arthritis Rheum; 2003 Feb; 48(2):516-22. PubMed ID: 12571862
[TBL] [Abstract][Full Text] [Related]
59. Bronchoalveolar lavage in sarcoidosis.
Drent M; Mansour K; Linssen C
Semin Respir Crit Care Med; 2007 Oct; 28(5):486-95. PubMed ID: 17975776
[TBL] [Abstract][Full Text] [Related]
60. Morphometric and DNA image analysis of bronchoalveolar lavage fluid macrophages nuclei in interstitial lung diseases with lymphocytic alveolitis.
Smojver-Jezek S; Peros-Golubicić T; Tekavec-Trkanjec J; Alilović M; Vrabec-Branica B; Juros Z; Mazuranić I
Coll Antropol; 2010 Mar; 34(1):123-9. PubMed ID: 20432740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
